Ymmunobio achieves 100% tumor eradication with their lead ADC YB-811 after only four doses (10 mg/kg) with no off-target toxicity!

What If You Could Give Cancer Patients Years They Never Expected?

Imagine a world where cancer patients aren't defined by their diagnosis, but by the possibilities ahead. Ymmunobio is building that world through NPTXR—a tumor-specific target that appears in 60–98% of solid cancers while sparing healthy tissue. This isn't just another biotech story. It's the rare convergence of first-in-class science, unprecedented tumor prevalence, and a platform spanning four transformative modalities: ADCs, bi-specific T-cell engagers, radiopharmaceuticals, and CAR-T. The preclinical proof is compelling; the opportunity is enormous. The time to join us is now. Meet with Ymmunobio and explore how NPTXR could reshape oncology and your portfolio.